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High-density lipoprotein (HDL) is a major carrier of cholesterol in the blood. Unlike other lipoproteins, physiological functions of
HDL inﬂuence the cardiovascular system in favorable ways except when HDL is modiﬁed pathologically. The cardioprotective
mechanism of HDL is mainly based on reverse cholesterol transport, but there has been an emerging interest in the anti-
inﬂammatoryandantioxidantrolesofHDL.TheselatteractivitiesofHDLarecompromisedinmanypathologicalstatesassociated
with inﬂammation. Further, abnormal HDL can become proinﬂammatory contributing to oxidative damage. In this paper,
we discuss the functional heterogeneity of HDL, how alterations in these particles in inﬂammatory states result in loss of
both antioxidant activity and reverse cholesterol transport in relation to atherosclerosis, and the need for assays to predict its
functionality.
1.Introduction
High-density lipoprotein (HDL) is a plasma lipoprotein
heterogeneous in origin, size, composition, and function. It
is a major carrier of cholesterol in blood, and unlike other
lipoproteins, physiological functions of HDL inﬂuence the
cardiovascular system favorably unless it is modiﬁed patho-
logically. The atheroprotective role of HDL is attributed to
i t sr o l ei np r o m o t i n gc e l l u l a rc h o l e s t e r o le ﬄux playing a key
role in reverse cholesterol transport.
Epidemiological studies have shown an inverse correla-
tion between plasma concentrations of HDL cholesterol and
cardiovascular risk [1]. The Framingham heart study which
followed 5209 men and women for a period of 12 years
reported that every 10mg/dl increase in HDL cholesterol is
associated with a signiﬁcant decrease in the relative risk for
coronary heart disease morbidity in 19% of men and 28% of
women [2].
2. Composition of HDL
HDL cholesterol is a macromolecular complex of lipids and
proteins and is highly heterogeneous in its physiochemical
properties, metabolism, and biological activity [3]. Such
heterogeneity is the result of diﬀerences in the relative
contents of apolipoproteins and lipids in the HDL. Multiple
subfractions of HDL can be identiﬁed in the plasma based
on density, size, charge, and composition. On the basis of
density, plasma HDL are divided into HDL2 (larger and less
dense) and HDL3 (smaller and denser), while agarose gel
electrophoresis further discriminates the basic HDL fraction
(α-lipoproteins) and a small fraction, pre-β-HDL.
Plasma HDL are spherical or discoidal particles of highly
hydrated density (1.063–1.21g/mL) due to elevated protein
content [4]. Discoidal HDL are small lipid-poor nascent
particles primarily made up of apolipoprotein A-I (Apo A-I)
embedded in a monolayer constituted of phospholipids and
free cholesterol. Spherical HDL are larger mature particles
additionally containing a hydrophobic core of cholesteryl
esters and small amounts of triglycerides.
2.1. Proteins. HDL is the smallest lipoprotein with the
highest density due to its high protein content. Apo A-
I is the major protein component of HDL cholesterol
making up 70% of its protein mass. Apo A-II comprises 15–
20%, and the remaining protein mass comes from minor2 Cholesterol
amphipathic proteins such as Apo C, Apo E, Apo D, Apo
M, and Apo A-IV; enzymes such as paraoxonase (PON)
1, platelet-activating factor acetylhydrolase (PAF-AH), and
glutathione peroxidase 1; lipid transfer proteins such as
lecithin:cholesterol acyltransferase (LCAT) and cholesteryl
e s t e rt r a n s f e rp r o t e i n( C E T P )[ 5].
2.2. Lipids. In addition to proteins, HDL cholesterol also
contains lipids including free and esteriﬁed chole-sterol;
phospholipids including phosphatidylcholine, phosphatidy-
lethanolamine, lysophosphatidylcholine, and plasmalogen;
free fatty acids; mono-, di-, and triacylglycerols; sphin-
golipids such as ceramide, sphingomyelins, sphingosine-
1-phosphate, lysosulphatide, and sphingosylphosphoryl-
choline [6].
3.AtheroprotectiveFunctionsofHDL
HDL cholesterol protects against atherosclerosis in multiple
ways including reverse cholesterol transport and using
antioxidant, anti-inﬂammatory, and antithrombotic mech-
anisms [7]. Although, our understanding of how HDL pro-
tectsagainstcoronaryarterydisease(CAD)isincomplete,we
have evidence for three major atheroprotective mechanisms
of HDL.
3.1. Reverse Cholesterol Transport. Reverse cholesterol trans-
port is the primary mechanism by which HDL exerts its
protective eﬀect. It involves transport of cholesterol from
peripheral blood cells, particularly macrophages, to the
liver for excretion as bile acids and free cholesterol. This
process is mediated by lipid transporter molecules such
as ATP-binding cassette transporter A1 and G1 (ABCA1
and ABCG1) and scavenger receptor B-1 (SR-BI) [8].
HDL can deliver cholesterol to the liver through hepatic
SR-BI, or alternatively cholesteryl esters within HDL are
exchanged for triglycerides in low-density lipoprotein (LDL)
or very low-density lipoprotein (VLDL) through CETP with
subsequent hepatic uptake via the LDL receptor pathway.
This potentially leads to recycling of cholesterol back into
the artery wall, which is central to the atheroprotective role
of HDL [8]. An overview of reverse cholesterol transport
as shown in Figure 1. CETP is a critical modulator of
HDL metabolism. CETP facilitates exchange of triglyceride
for cholesteryl esters between triglyceride-rich lipoprotein
particles (VLDL, IDL, and LDL) and HDL. This exchange
results in increased cholesterol content of triglyceride-rich
lipoprotein particles and cholesterol depletion of HDL
particles. The small, cholesterol-deplete particles are often
excreted in the urine. In metabolic diseases, such as type
2 diabetes and metabolic syndrome, elevated CETP activity
results in increased cholesteryl ester (CE) transfer from HDL
to triglyceride- (TG-) rich lipoproteins and in reciprocal
TG transfer, producing TG-enriched HDL and decreasing
H D Lc h o l e s t e r o ll e v e l s[ 9]. Conversely, CETP deﬁciency
reduces the exchange of TG and CE between HDL and
TG-rich lipoproteins and elevates HDL cholesterol due to
CE retention. As a consequence, increased CETP activity is
thought to be proatherogenic in humans [10].
3.2. Inhibition of LDL Oxidation. In multicellular organisms,
the major role of lipoproteins is extracellular transport of
lipids.ApoA-IisamajorLDLproteinwithabindingdomain
for LDL deposition in the extracellular matrix of many
tissues, especially arteries susceptible to atherosclerosis. LDL
binding to the subendothelial space causes cells to oxidize
LDL lipids evoking the cells to secrete monocyte chemoat-
tractant protein (MCP-1) and inducing an inﬂammatory
response [11]. HDL in normal state abolishes the extracellu-
lartransportoflipidsbypreventingLDLoxidation, secretion
of MCP-1, and the inﬂammatory response. Furthermore,
HDL comprises a series of antioxidant enzymes which
protect LDL from oxidation. Oxidized lipids are transferred
to HDL from LDL and are hydrolyzed by HDL-associated
PON1, LCAT, and PAF-AH enzymes [12, 13].
3.3. Anti-Inﬂammatory Properties. The anti-inﬂammatory
activity of HDL is explained by its ability to selectively
decrease endothelial cell adhesion molecules which facilitate
the binding of mononuclear cells to the vessel wall and
promote lesion development, thereby protecting against
CAD [14]. HDL limits expression of cytokines such as tumor
necrosis factor-α (TNF-α) and interleukin-1 that mediate
upregulation of leukocyte-endothelial adhesion molecules.
The ability of HDL to inhibit adhesion molecule expression
could be mediated by apolipoproteins, not only by Apo
A-I, but also by phospholipids, including sphingosine-1-
phosphate and sphingosylphosphorylcholine [15, 16].
However, HDL has multiple additional endothelial and
antithrombotic actions that may also aﬀord cardiovascular
protection which were discussed in detail in some recent
reviews [17]. HDL modulates endothelial function, probably
by stimulating endothelial nitric oxide (NO) production
which is an atheroprotective signaling molecule. HDL
stimulates NO production by upregulating endothelial NO
synthase (eNOS) expression by maintaining the lipid envi-
ronmentin caveolae,whereeNOSis colocalized withpartner
signaling molecules and by stimulating eNOS as a result of
kinase cascade activation by the high-aﬃnity HDL receptor
SR-BI. HDL also protects endothelial cells from apoptosis
and promotes their growth and their migration via SR-BI-
initiated signaling.
4.HDLMay Not Be Protective:
DysfunctionalHDL
HDL and cardiovascular disease show an inverse correlation
[1]. However, recent studies indicate that higher HDL levels
may not always be protective and can become dysfunctional
losing their cardioprotective eﬀects [18]. HDL particles
can vary in size, density, composition, and functional
properties inﬂuencing their association with atherosclerosis
[8]. Further, emerging evidence suggests that HDL functionCholesterol 3
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Figure1:Anoverviewofreversecholesteroltransport.HDLpromotestheprocessofreversecholesteroltransport,wherebyexcesscholesterol
present in the macrophage is eﬄuxed to HDL and ultimately delivered to liver for excretion. HDL: high-density lipoprotein; CE: cholesterol
ester; FC: free cholesterol; Apo A-I: apolipoprotein A-I; ABCA1: adenosine triphosphate-binding cassette transporter A1; LCAT: lecithin
cholesterol acyltransferase; CETP: cholesterol ester transfer protein; PLTP: phospholipid transfer protein; LDL: low-density lipoprotein;
LDL-R: low-density lipoprotein receptor; SR-BI: scavenger receptor class B-type I; VLDL: very low-density lipoprotein; TGL: triglycerides.
is not always accurately predicted by HDL cholesterol
levels.
HDL acts as an anti-inﬂammatory molecule in healthy
individuals. However, in those with chronic illnesses such
as diabetes that are characterized by systemic oxidative
stress and inﬂammation, HDL may actually promote the
inﬂammatory response (i.e., it may become proinﬂamma-
tory). More than a decade ago, Lenten and colleagues [19]
reported that during an acute-phase response in animals
or humans following surgery, HDL properties changed to
become proinﬂammatory. These observations have formed
the basis for subsequent studies evaluating the proinﬂamma-
torypropertiesofHDL.Atbasalstate,functionalHDLshows
high levels of antioxidants, active antioxidant proteins, and
antioxidant enzymes with anti-inﬂammatory activity. How-
ever, when antioxidant and anti-inﬂammatory functions of
HDL are overwhelmed by pathological processes such as
inﬂammation, HDL is converted into a dysfunctional, proin-
ﬂammatory particle that cannot promote cholesterol eﬄux
or prevent LDL oxidation [20]. This dysfunctional HDL
shows decreased levels and activities of anti-inﬂammatory
and antioxidant factors, such as Apo A-I and PON1.
Dysfunctional HDL contains oxidized phospholipids and
proinﬂammatory proteins, such as serum amyloid A (SAA)
and ceruloplasmin. Evidence shows that many pathological
processes associated with systemic inﬂammation including
chronic heart disease, metabolic syndrome, chronic kidney
disease, infections, and rheumatic diseases are characterized
by the presence of dysfunctional or proinﬂammatory HDL
[21].
An oxidative environment is produced when an acute-
phase response occurs as a result of nonspeciﬁc immunity.
Thus, HDL appears to be part of the innate immune system
and can be either proinﬂammatory or anti-inﬂammatory
depending on the presence or absence of an acute-phase
response and systemic inﬂammation.
Change in HDL function parallels changes in HDL
composition. Inﬂammation induces major changes in HDL
levels and composition. Inﬂammatory cytokines such as
TNF-α and interleukin-6 (IL-6) enhance expression levels
of SAA and group IIA secretory phospholipase A2 (sPLA2-
IIA) altering apolipoprotein content and levels [22, 23].
Myeloperoxidase (MPO) is a key inﬂammatory mediator of
macrophages and other leukocytes, and systemic inﬂamma-
tion is thought to convert HDL to a dysfunctional form
that loses its antiatherogenic eﬀects. Modiﬁcation of HDL
composition by acute-phase response and oxidative stress
is summarized in Figure 2. The pro-oxidant acute-phase
reactants namely SAA and ceruloplasmin are associated with
the formation of proinﬂammatory HDL along with Apo-
j, also called clusterin [24]. The acute-phase HDLs are
depleted in cholesterol esters but enriched in free cholesterol,4 Cholesterol
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Figure 2: Model of bidirectional conversion of HDL from anti-inﬂammatory to proinﬂammatory. Normal anti-inﬂammatory HDLs
are rich in apolipoproteins (ovals) and antioxidant enzymes (squares). After exposure to pro-oxidants, oxidized lipids, and proteases,
proinﬂammatoryHDLshavelesslipoproteinandthemajortransporterapolipoproteinA-Iaredisabledbytheadditionofchlorine,nitrogen,
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oxidant acute-phase proteins are added to the particle (serum amyloid A (SAA) and ceruloplasmin). “Apo A-I ↑”, “PON1 ↑” indicates that
the number of respective molecules present in anti-inﬂammatory HDL is more when compared to that of proinﬂammatory HDL. Apo
J: apolipoprotein J; CE: cholesterol ester; PON1: paraoxonase-1; GSH: glutathione; SAA: serum amyloid A; Apo A-I: apolipoprotein A-I;
Apo-AII: apolipoprotein A-II; LCAT: lecithin cholesterol acyltransferase; PAF-AH: platelet-activating acyl hydrolase.
triglycerides, and free fatty acids, but none of them can
participate in reverse cholesterol transport or antioxidation
[12, 25].
HDL undergoes pronounced structural and functional
modiﬁcations in acute phase and inﬂammation. The major
protein in HDL, Apo A-I, might be reduced because of
decreased Apo A-I synthesis, accelerated HDL catabolism,
and Apo A-I replacement by SAA. SAA is a pro-oxidant
acute-phase reactant associated not only with disabling the
anti-inﬂammatory role of HDL but also with creation of
proinﬂammatoryHDL[26,27].Itismainlyofhepaticorigin,
and circulating levels can be induced to increase up to 1,000-
fold in the presence of inﬂammation. Like C-reactive protein
(CRP),elevatedplasmalevelsofSAArepresentanimportant,
although weaker, cardiovascular risk factor. Recent studies
suggest that Apo A-I oxidation by MPO results in the
lossofHDL-mediated,antiapoptotic,andanti-inﬂammatory
activities [28]. During acute and chronic inﬂammation,
the content and functions of HDL can change drastically
converting atheroprotective HDL to proatherogenic HDL.
HDL lipid composition might equally be altered during
inﬂammation. Enrichment in TG with depletion of CE in
the HDL core is the most frequent abnormality of HDL lipid
composition and occurs in hypertriglyceridemic states asso-
ciated with decreased activity of lipoprotein lipase, hepatic
lipase, LCAT, or a combination of these. All these metabolic
alterations are frequently observed in the acute phase and
during inﬂammation [29]. In addition, HDL triglyceride
content can also be increased in hypertriglyceridemia as
a consequence of elevated CETP activity. CETP-mediated
replacement of cholesteryl esters by triglycerides in the
HDL core results in decreased plasma HDL cholesterol
levels, which is another feature of the acute-phase response.
Similar elevation in HDL-TG, decrease in HDL cholesterol,
and increase in inﬂammatory markers are observed in the
postprandial phase [30]. An elevated content of triglycerides
might, therefore, represent a critical factor that lowers both
HDL particle stability and plasma residence time. Acute-
phase HDL also contains elevated levels of nonesteriﬁed fatty
acids, lysophosphatidylcholines, and isoprostanes compared
with normal HDL; in addition, CE levels are decreased
[31].
Activities of the HDL-associated enzymes PON1, PAF-
AH, and LCAT were indeed decreased in the acute-phase
response. Van Lenten et al. noted that activities of PON1
and PAF-AH, that is, the anti-inﬂammatory properties of
HDL, were restored upon resolution of the acute-phase
response [19]. Further studies reported that PON1 and PAF-
AH were partly responsible for the ability of HDL to inhibit
LDL oxidation and the inﬂammatory response induced
[32–34]. As part of the acute-phase response, activities of
HDL-associated enzymes including PON1, PAF-AH, LCAT,
CETP, and phospholipid transfer protein (PLTP) can be
compromised, made dysfunctional or both [35].
Alterations occurring in HDL composition and meta-
bolism due to inﬂammation are intimately associated with
impaired biological activities. The cholesterol eﬄux capacity
of HDL is considerably impaired during inﬂammation. Apo
A-I,themajorproteinofHDL,playsanimportant roleinthe
cellular cholesterol eﬄux, and the replacement of Apo A-I by
SAA during inﬂammation can, therefore, have a signiﬁcant
impact on eﬄux. Enrichment of HDL with SAA results in
increased HDL binding to macrophages, decreased choles-
teroleﬄuxfrommacrophages,andincreasedselectiveuptake
of CE by macrophages [36, 37]. Importantly, SAA selectively
impairs cholesterol eﬄux properties of small, dense HDL3
particles. Recently, McGillicuddy et al. provided evidence in
humans and mice indicating that acute-phase HDL enriched
in SAA induced by acute endotoxaemia have an impaired
capacity to remove cholesterol from macrophages [38].Cholesterol 5
The antioxidative activities of HDL might equally
become impaired in the presence of inﬂammation due to
the replacement of Apo A-I by SAA and altered enzymatic
activities [39]. Indeed, antioxidative deﬁciency of HDL
relative to LDL oxidation by artery wall cells is observed in
the acute phase, concomitant with decreases in the activity
of PON1 and PAF-AH. All these mechanisms might limit
the capacity of HDL to inactivate oxidized phospholipids,
resulting in their elevated accumulation in LDL.
These altered HDLs are proinﬂammatory enhancing
LDL oxidation and attracting monocytes to engulf the
oxidizedLDLs.LipidsintheseHDLsarethemselvesoxidized.
Van Lenten et al. were the ﬁrst to report that during an
acute-phase response, HDL loses its ability to inhibit LDL
oxidation. They noted that HDL from normal rabbits and
humans prevented LDL oxidation and LDL-induced MCP-1
productioninculturesofhumanarterywallcells.Incontrast,
HDL isolated from the same source at the peak of an acute-
phase response was less eﬃcient in inhibiting LDL oxidation
and increased MCP-1 production [19].
According to recent studies in patients with CAD,
HDL is not only ineﬀective as an anti-inﬂammatory and
antioxidant but is actually a proinﬂammatory and pro-
oxidant promoting LDL oxidation. A study from Corsetti et
al. suggested that raised HDL cholesterol levels and raised
CRP levels may result in increased risk of cardiovascular
disease. They also suggested that in patients with elevated
levels of HDL and CRP, addition of CETP activity results in a
higher CAD risk potentially explaining the negative ﬁndings
from the torcetrapib studies [40].
The Thrombogenic Factors and Recurrent Coronary
Events (THROMBO) postinfarction study by Corsetti et
al. showed the same results in a subgroup of nondiabetic
patients with high CRP levels who showed recurrent risk
with increasing HDL cholesterol levels [41]. Extending these
studies to a healthy population (Prevention of Renal and
Vascular End-Stage Disease study) to determine whether
primary coronary risk acted similarly identiﬁed a high-
risk subgroup at high HDL cholesterol and CRP levels
with presumptive evidence for large HDL particles. It also
identiﬁed a second high-risk group with high CRP levels and
low HDL levels as expected from many previous studies [42].
Subgroup patients had low levels of lipoprotein-associated
phospholipase A2 (Lp-PLA2) and large HDL particles.
Rein et al. studied the roles of the metabolic syndrome,
HDL cholesterol, and coronary atherosclerosis in subclinical
inﬂammation and identiﬁed that the association of the
metabolic syndrome with subclinical inﬂammation is driven
by low HDL cholesterol [43].
5. Need for the FunctionalTests
HDL cholesterol levels do not predict functionality and
composition of HDL. The cholesteryl ester transfer protein
inhibitor,torcetrapibthatdespiteincreasingHDLcholesterol
concentrations failed the trial, has brought issues of HDL
heterogeneity and function into sharp focus. In a controlled
prospective trial on a combination of the HDL level-raising
CETP inhibitor, torcetrapib, and statin by Barter et al., the
HDL levels increased in 12 months in the torcetrapib/statin
group, but the frequency of atherosclerotic events was
signiﬁcantly higher than the placebo plus statin group.
However,thequalitativecharacteroftheincreasedHDLswas
not measured in the study [44].
Plasma concentrations of HDL are insuﬃcient to capture
thefunctionalvariationinHDLparticlesalongwiththeasso-
ciated cardiovascular risk. These levels are also inadequate
for assessing the potential therapeutic eﬃcacy of novel HDL-
targeted therapies. In light of recent developments, there is
a growing need to identify other HDL-related subclasses and
functions and biomarkers that better predict cardiovascular
risk and can be used to assess the clinical beneﬁts of novel
HDL-targeted therapies.
Several ex vivo and in vitro assays have been developed to
assess HDL’s heterogeneity and its various functions. These
testsarenotyetcommerciallyavailablebutholdpromisethat
we may be able to go beyond measuring the HDL cholesterol
level and determine the functional characteristics of the
patient’s HDL. Substantial progress has been made in the
development of robust and reproducible methods for assess-
ment of HDL subclasses, and many of these assays are now
commercially available. HDL heterogeneity was measured
using various methods like analytical ultracentrifugation,
gradient gel electrophoresis, 2-dimensional electrophoresis,
and nuclear magnetic resonance spectroscopy. In contrast to
the robust state of clinical chemistry regarding HDL subfrac-
tions, the laboratory assessment of HDL function remains in
its infancy [45]. In vitro assays of HDL function have been
developed by various research laboratories but are laborious,
nonstandardized,andpoorlyvalidatedwithregardtohuman
outcomes.There is an urgent need forproducing meaningful
and reproducible assays for various functions of HDL
cholesterol like cholesterol eﬄux and reverse cholesterol
transport, antioxidant, anti-inﬂammatory functions which
are validated in large population.
6. Conclusions
Measuring HDL cholesterol levels may not predict func-
tionality and anti-inﬂammatory properties of HDL. For
this, we need to test the composition, functionality, and
inﬂammatory properties of HDL. Though there are robust
and reproducible methods for assessment of HDL hetero-
geneity, there are no widely available tests for measuring
HDL functionality in clinical practice. In vitro assays for
HDL function have been developed by various research labs
but are nonstandardized and poorly validated. As such, there
is a need for further research into development of standard
methodstousetheseassaysinlargepopulation-basedstudies
and test whether they predict risk independent of HDL
cholesterol concentrations.
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